Clinical Trial Update: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ibrutinib in combination with venetoclax for mantle cell lymphoma has completed, and its results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Mantle-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2025-07-22